Reputation and Power (eBook)

Organizational Image and Pharmaceutical Regulation at the FDA

Daniel Carpenter (Autor)

eBook Download: PDF

2014
856 Seiten
Princeton University Press (Verlag)
978-1-4008-3511-9 (ISBN)

Infos

How the FDA became the world's most powerful regulatory agencyThe U.S. Food and Drug Administration is the most powerful regulatory agency in the world. How did the FDA become so influential? And how exactly does it wield its extraordinary power? Reputation and Power traces the history of FDA regulation of pharmaceuticals, revealing how the agency's organizational reputation has been the primary source of its power, yet also one of its ultimate constraints.Daniel Carpenter describes how the FDA cultivated a reputation for competence and vigilance throughout the last century, and how this organizational image has enabled the agency to regulate an industry as powerful as American pharmaceuticals while resisting efforts to curb its own authority. Carpenter explains how the FDA's reputation and power have played out among committees in Congress, and with drug companies, advocacy groups, the media, research hospitals and universities, and governments in Europe and India. He shows how FDA regulatory power has influenced the way that business, medicine, and science are conducted in the United States and worldwide. Along the way, Carpenter offers new insights into the therapeutic revolution of the 1940s and 1950s; the 1980s AIDS crisis; the advent of oral contraceptives and cancer chemotherapy; the rise of antiregulatory conservatism; and the FDA's waning influence in drug regulation today.Reputation and Power demonstrates how reputation shapes the power and behavior of government agencies, and sheds new light on how that power is used and contested.Some images inside the book are unavailable due to digital copyright restrictions.

Autor

Daniel P. Carpenter is the Allie S. Freed Professor of Government at Harvard University. He is the author of The Forging of Bureaucratic Autonomy: Reputations, Networks, and Policy Innovation in Executive Agencies, 1862-1928 (Princeton).

Produkt-Details

• Erscheint lt. Verlag: 24.4.2014
• Reihe/Serie: Princeton Studies in American Politics
• Reihe/Serie: Princeton Studies in American Politics: Historical, International, and Comparative Perspectives
• Zusatzinfo: 13 halftones. 17 line illus. 13 tables.
• Verlagsort: Princeton
• Sprache: englisch
• Themenwelt: Geisteswissenschaften ► Geschichte
• Themenwelt: Medizin / Pharmazie ► Pharmazie
• Themenwelt: Recht / Steuern ► Arbeits- / Sozialrecht ► Sozialrecht
• Themenwelt: Recht / Steuern ► EU / Internationales Recht
• Themenwelt: Recht / Steuern ► Privatrecht / Bürgerliches Recht ► Medizinrecht
• Themenwelt: Sozialwissenschaften ► Politik / Verwaltung ► Politische Systeme
• Themenwelt: Sozialwissenschaften ► Politik / Verwaltung ► Staat / Verwaltung
• Themenwelt: Technik
• Schlagworte: administrative law • Adverse effect • Adverse Event • advisory board • Amendment • American Medical Association • Amygdalin • Bristol-Myers Squibb • bureaucrat • Cambridge University Press • Cardiology • Career • Chemotherapy • Clinical investigator • Clinical Pharmacology • clinical research • clinical study • clinical trial • Complication (medicine) • Consideration • Consumer Protection • Cosmetics • Criticism • deference • Deliberation • Disease • distrust • Dosage form • drug development • Drug Evaluation • efficacy • Employment • epidemiology • Experiment • Federal Trade Commission • Funding • Genentech • General Counsel • Generic drug • Governance • government agency • Harvard University Press • Health Care • health policy • human subject research • Indication (medicine) • Institution • Investigational New Drug • johns hopkins • Journalism • Legislation • Management of HIV/AIDS • medical director • Medical Officer (AYUSH) • Medical Research • medical school • National Institutes of Health • New drug application • Newsweek • Off-label use • Oncology • Pathology • Pediatrics • Penicillin • Pfizer • pharmaceutical drug • Pharmaceutical Industry • Pharmaceutical Policy • Pharmacist • pharmacology • Pharmacy • Phases of clinical research • Physician • Political Economy • Political Science • Politician • Politics • Precedent • prescription drug • Provision (contracting) • Public Health • quackery • Ralph Nader • Regime • Regulation • Regulatory Affairs • Regulatory Agency • Requirement • Research and Development • rulemaking • Scientist • Statute • Suggestion • Surrogate Endpoint • Textbook • Thalidomide • The Wall Street journal • Toxicity • Toxicology • trade name
• ISBN-10: 1-4008-3511-9 / 1400835119
• ISBN-13: 978-1-4008-3511-9 / 9781400835119